Evidence map›Paper›PMID 26443752›Full record

ArticleJournal of the International AIDS Society2015

Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care.

Angela Cescon, Sophie Patterson, Colin Davey, Erin Ding, Janet M Raboud, Keith Chan, Mona R Loutfy, Curtis Cooper, Ann N Burchell, Alexis K Palmer and 8 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 1 country.

Angela CesconBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Sophie PattersonBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Colin DaveyBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Erin DingBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Janet M RaboudToronto General Research Institute, University Health Network, Toronto, Canada.
Keith ChanBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Mona R LoutfyUniversity of Toronto, Toronto, Canada.
Curtis CooperDepartment of Medicine, University of Ottawa, Ottawa, Canada.
Ann N BurchellUniversity of Toronto, Toronto, Canada.
Alexis K PalmerBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Christos TsoukasFaculty of Medicine, McGill University, Montreal, Canada.
Nima MachoufClinique Médicale l'Actuel, Montreal, Canada.
Marina B KleinFaculty of Medicine, McGill University, Montreal, Canada.
Sean B RourkeUniversity of Toronto, Toronto, Canada.
Anita RachlisSunnybrook Health Sciences Centre, Toronto, Canada.
Robert S HoggBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Julio S G MontanerBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
CANOC Collaboration
AIDS Vancouver · CAMcGill University · CASimon Fraser University · CANOSM University · CAOntario HIV Treatment Network · CASt. Francis Xavier University · CASunnybrook Health Science Centre · CAUniversity Health Network · CAUniversity of British Columbia · CAUniversity of Ottawa · CAUniversity of Toronto · CAWomen's College Hospital · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

introductionCombination antiretroviral therapy (ART) significantly decreases morbidity, mortality and HIV transmission. We aimed to characterize the timing of ART initiation based on CD4 cell count from 2000 to 2012 and identify factors associated with late initiation of treatment.

methodsParticipants from the Canadian Observational Cohort (CANOC), a multi-site cohort of HIV-positive adults initiating ART naively after 1 January 2000, in three Canadian provinces (British Columbia, Ontario and Québec) were included. Late initiation was defined as a CD4 count <200 cells/mm(3) or an AIDS-defining illness before ART initiation (baseline). Temporal trends were assessed using the Cochran-Armitage test, and independent correlates of late initiation were identified using logistic regression.

resultsIn total, 8942 participants (18% female) of median age 40 years (Q1-Q3 33-47) were included. The median baseline CD4 count increased from 190 cells/mm(3) (Q1-Q3 80-320) in 2000 to 360 cells/mm(3) (Q1-Q3 220-490) in 2012 (p<0.001). Overall, 4274 participants (48%) initiated ART with a CD4 count <200 cells/mm(3) or AIDS-defining illness. Late initiation was more common among women, non-MSM, older individuals, participants from Ontario and BC (vs. Québec), persons with injection drug use (IDU) history and individuals starting ART in earlier calendar years. In sub-analysis exploring recent (2008 to 2012) predictors using an updated CD4 criterion (<350 cells/mm(3)), IDU and residence in BC (vs. Québec) were no longer significant correlates of late initiation.

conclusionsThis analysis documents increasing baseline CD4 counts over time among Canadians initiating ART. However, CD4 counts at ART initiation remain below contemporary treatment guidelines, highlighting the need for strategies to improve earlier engagement in HIV care.

Indexed as

Public HealthAdultAnti-HIV AgentsCanadaCD4 Lymphocyte CountFemaleHIV InfectionsHumansMaleMiddle AgedTime FactorsAnti-HIV AgentsAIDSantiretroviral therapyCanadaHIVHIV carelate initiationpublic health

Identifiers

PMID26443752
PMCPMC4595457
OpenAlexW1822763080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.